Press Releases

Quanterix Corporation Releases Operating Results for Third Quarter 2019

Strong revenue growth and successful early launch of new HD-X Analyzer | November 06, 2019

Billerica, Mass.

Siemens Healthineers Enters into License and Supply Arrangement with Quanterix for Access to Neurofilament Light (Nf-L) Antibodies to Develop Nf-L Assays

November 04, 2019

BILLERICA, Mass.--(BUSINESS WIRE)--

Quanterix Simoa Technology Unlocks Low-Level Markers Critical to Rapid Triage Test in Study for Active Pulmonary Tuberculosis

October 25, 2019

Findings by leading researchers demonstrate the promise and relevance of Simoa in vast application areas.

Quanterix to Release Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019

October 22, 2019

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for third quarter 2019

Quanterix Announces Recipients of Annual Accelerator Grant Program

Winners of the second annual call for research proposals focuses on predictive biomarkers of neurodegeneration, neurological injury and inflammation in relation to cognitive functioning and brain connectivity among breast cancer survivors | October 03, 2019

BILLERICA, Mass.--(BUSINESS WIRE)--

Quanterix Serum Nf-L Assay Powers Key Trial and Study Results Presented at ECTRIMS 2019

Presentations by leading researchers demonstrate promise and relevance of Neurofilament light chain (Nf-L) as a reliable disease biomarker for MS | September 18, 2019

BILLERICA, Mass.--(BUSINESS WIRE)--